Dianthus Therapeutics Stock Forward View - Simple Regression
| DNTH Stock | 79.61 1.06 1.35% |
The Simple Regression forecast reference data for Dianthus Therapeutics is based on the equity's recent trading history. Forecast values and accuracy indicators are summarized on this page for reference. This reference information is provided for analytical context.
The Simple Regression forecasted value of Dianthus Therapeutics on the next trading day is projected to be 77.25 with a mean absolute deviation of 5.63 and the sum of the absolute errors of 343.45.In general, regression methods applied to historical equity returns or prices series is an area of active research. In recent decades, new methods have been developed for robust regression of price series such as Dianthus Therapeutics historical returns. These new methods are regression involving correlated responses such as growth curves and different regression methods accommodating various types of missing data. The Simple Regression projections for Dianthus Therapeutics are reference data based on historical daily prices and are provided as informational context. Simple Regression Price Forecast For the 26th of March
Given 90 days horizon, the Simple Regression forecasted value of Dianthus Therapeutics on the next trading day is expected to be 77.25 with a mean absolute deviation of 5.63 , mean absolute percentage error of 46.27 , and the sum of the absolute errors of 343.45 .Please note that although there have been many attempts to predict Dianthus Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Dianthus Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Dianthus Therapeutics | Dianthus Therapeutics Price Prediction | Research Analysis |
Forecasted Value
Forecasting Dianthus Therapeutics for the next session involves measuring the model's historical ability to define credible downside and upside scenarios. The projected forecast band currently runs from roughly 72.10 on the downside to about 82.39 on the upside.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Regression forecasting method's relative quality and the estimations of the prediction error of Dianthus Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Dianthus Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 121.945 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 5.6303 |
| MAPE | Mean absolute percentage error | 0.1012 |
| SAE | Sum of the absolute errors | 343.4474 |
Other Forecasting Options for Dianthus Therapeutics
Volatility clustering is a well-documented feature of Dianthus Stock price data where periods of large moves tend to follow other large moves. When Dianthus Therapeutics' RSI reaches extreme levels, it often precedes a short-term price correction or consolidation. Seasonal patterns in Dianthus Therapeutics' returns can persist when driven by structural factors like earnings calendars or index rebalancing.Dianthus Therapeutics Related Equities
Investors studying Dianthus Therapeutics often look at related stocks within the Health Care space to gauge pricing and results. Key comparison metrics include price-to-earnings, profit margin, and revenue growth across Dianthus Therapeutics' peer group. Sector-wide trends across this peer group can help split company-level factors from broader forces.
| Risk & Return | Correlation |
Dianthus Therapeutics Market Strength Events
Analyzing market strength indicators for Dianthus Therapeutics enables investors to understand relative stock momentum. These tools help identify favorable windows for position changes in Dianthus Therapeutics. Market strength indicators support more precise timing of Dianthus Therapeutics positions across market cycles.
| Accumulation Distribution | 40149.38 | |||
| Daily Balance Of Power | 0.3302 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 80.55 | |||
| Day Typical Price | 80.23 | |||
| Price Action Indicator | -0.41 | |||
| Period Momentum Indicator | 1.06 |
Dianthus Therapeutics Risk Indicators
Identifying and analyzing Dianthus Therapeutics' key risk indicators is a foundational step in projecting how its price may evolve. This process involves measuring the level of investment risk in Dianthus Therapeutics' and determining how best to manage it. Studying Dianthus Therapeutics' risk indicators helps investors understand the risk level of dianthus stock.
| Mean Deviation | 3.53 | |||
| Semi Deviation | 2.65 | |||
| Standard Deviation | 5.0 | |||
| Variance | 24.96 | |||
| Downside Variance | 11.33 | |||
| Semi Variance | 7.03 | |||
| Expected Short fall | -4.10 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Dianthus Therapeutics
A coverage review of Dianthus Therapeutics shows when the security is attracting above-average attention from contributors and market observers. This is most useful when investors want to understand why a security is suddenly drawing more public discussion.
Contributor Headline
Latest Perspective From Macroaxis
Dianthus Therapeutics Short Properties
Short-interest signals around Dianthus Therapeutics can help investors judge whether skeptical positioning is starting to pressure price predictability and market tone. The practical goal is to identify when the balance between long and short participation may be changing the quality of the setup.
| Common Stock Shares Outstanding | 37.8 M | |
| Cash And Short Term Investments | 404.3 M |